GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Foresee Pharmaceuticals Co Ltd (ROCO:6576) » Definitions » Net-Net Working Capital

Foresee Pharmaceuticals Co (ROCO:6576) Net-Net Working Capital : NT$1.41 (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Foresee Pharmaceuticals Co Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Foresee Pharmaceuticals Co's Net-Net Working Capital for the quarter that ended in Sep. 2024 was NT$1.41.

The industry rank for Foresee Pharmaceuticals Co's Net-Net Working Capital or its related term are showing as below:

ROCO:6576's Price-to-Net-Net-Working-Capital is ranked worse than
91.71% of 422 companies
in the Drug Manufacturers industry
Industry Median: 7.915 vs ROCO:6576: 60.57

Foresee Pharmaceuticals Co Net-Net Working Capital Historical Data

The historical data trend for Foresee Pharmaceuticals Co's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foresee Pharmaceuticals Co Net-Net Working Capital Chart

Foresee Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.71 11.43 7.94 3.32 6.24

Foresee Pharmaceuticals Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.53 6.24 5.66 4.30 1.41

Competitive Comparison of Foresee Pharmaceuticals Co's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Foresee Pharmaceuticals Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Foresee Pharmaceuticals Co's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Foresee Pharmaceuticals Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Foresee Pharmaceuticals Co's Price-to-Net-Net-Working-Capital falls into.



Foresee Pharmaceuticals Co Net-Net Working Capital Calculation

Foresee Pharmaceuticals Co's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1352.179+0.75 * 65.912+0.5 * 126.799-616.932
-0-0)/135.851
=6.24

Foresee Pharmaceuticals Co's Net-Net Working Capital (NNWC) per share for the quarter that ended in Sep. 2024 is calculated as

Net-Net Working Capital(Q: Sep. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(839.809+0.75 * 52.789+0.5 * 143.949-758.896
-0-0)/136.813
=1.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Foresee Pharmaceuticals Co  (ROCO:6576) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Foresee Pharmaceuticals Co Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Foresee Pharmaceuticals Co's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Foresee Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 19-3, Sanchong Road, 9th Floor-2, Nangang District, Taipei, TWN, 115
Foresee Pharmaceuticals Co Ltd is engaged in the development and commercialization of new drugs using its proprietary drug delivery technology. Its main activity is to apply its Stabilized injectable formulation(SIF) platform technology to produce the products for anticancer and treatment of chronic disease. Its SIF product pipeline includes FP-001 for prostate cancer, FP-004 for Opioid drug addiction/Pain, FP-011 for Breast Cancer/Prostate Cancer, FP-016 for neurological diseases, and others. All of its revenue is generated from Taiwan.

Foresee Pharmaceuticals Co Headlines

No Headlines